Trials / Completed
CompletedNCT03259035
NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 58 (actual)
- Sponsor
- Canadian Cancer Trials Group · Network
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out the effects of chemotherapy followed by less invasive surgery on patients and their early rectal cancer. The approach of this trial will be considered a success if at least 65% of participants are able to keep the rectum.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Folfox Protocol | 6 cycles of q2weekly FOLFOX, or |
| DRUG | Capox | 4 cycles of q3weekly CAPOX |
Timeline
- Start date
- 2018-06-29
- Primary completion
- 2024-04-08
- Completion
- 2024-04-25
- First posted
- 2017-08-23
- Last updated
- 2026-04-09
- Results posted
- 2024-10-10
Locations
11 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03259035. Inclusion in this directory is not an endorsement.